am0c01768_si_001.pdf (1.53 MB)
Intrinsic Biotaxi Solution Based on Blood Cell Membrane Cloaking Enables Fullerenol Thrombolysis In Vivo
journal contribution
posted on 2020-03-17, 16:03 authored by Kui Chen, Yujiao Wang, Haojun Liang, Shibo Xia, Wei Liang, Jianglong Kong, Yuelan Liang, Xia Chen, Meiru Mao, Ziteng Chen, Xue Bai, Jiaxin Zhang, Jiacheng Li, Ya-nan Chang, Juan Li, Gengmei XingWe
report the construction of blood cell membrane cloaked mesoporous
silica nanoparticles for delivery of nanoparticles [fullerenols (Fols)]
with fibrinolysis activity which endows the active Fol with successful
thrombolysis effect in vivo. In vitro, Fols present excellent fibrinolysis activity, and the Fol with
the best fibrinolysis activity is screened based on the correlation
between Fols’ structure and their fibrinolysis activity. However,
the thrombolytic effect in vivo is not satisfactory.
To rectify the unsatisfactory situation and avoid the exogenous stimuli,
a natural blood cell membrane cloaking strategy with loading the active
Fol is chosen to explore as a novel thrombolysis drug. After cloaking,
the therapeutic platform prolongs blood circulation time and enhances
the targeting effect. Interestingly, compared with platelet membrane
cloaking, red blood cell (RBC) membrane cloaking demonstrates stronger
affinity with fibrin and more enrichment at the thrombus site. The
Fol with RBC cloaking shows quick and efficient thrombolysis efficacy in vivo with less bleeding risk, more excellent blood compatibility,
and better biosafety when compared with the clinical drug urokinase
(UK). These findings not only validate the blood cell membrane cloaking
strategy as an effective platform for Fol delivery on thrombolysis
treatment, but also hold a great promising solution for other active
nanoparticle deliveries in vivo.